Drugs / MMR Bio-Manguinhos
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01991899 | Feb → Dec 2015 | chickenpox, measles, mumps infectious disease, rubella | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MMR Bio-Manguinhos | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01991899 ↗ |
| Modality | Vaccine | “combined measles , mumps and rubella vaccine” NCT01991899 ↗ |
| Route | Subcutaneous | “Application of a 0.5 ml dose, subcutaneous” NCT01991899 ↗ |